Division of Hematology/Oncology

Share This Page:

Robert H. Vonderheide, MD, DPhil

faculty photo
John H. Glick Abramson Cancer Center Professor
Attending Physician, Hospital of the University of Pennsylvania, Philadelphia, PA
Investigator, Abramson Family Cancer Research Institute
Member, Abramson Cancer Center, University of Pennsylvania School of Medicine
Attending Physician, VA Medical Center, Philadelphia, PA
Program Co-Leader, Immunobiology Program, Abramson Cancer Center, University of Pennsylvania
Associate Director for Translational Research, Abramson Cancer Center, University of Pennsylvania
Director, Penn Pancreatic Cancer Research Center
Vice Chief for Research, Hematology-Oncology Division, Perelman School of Medicine, University of Pennsylvania
Department: Medicine

Contact information
12 South Pavilion
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: 215-662-3929
Fax: 215-573-2652
Lab: 215-746-8901 Mark Sudell
Graduate Group Affiliations
BSc (Chemical Engineering)
University of Notre Dame, 1985.
DPhil (Immunology)
Oxford University, 1989.
Harvard Medical School, 1993.
Post-Graduate Training
Intern in Medicine, Massachusetts General Hospital, 1993-1994.
Resident, Internal Medicine, Massachusetts General Hospital, 1994-1996.
Fellow in Hematology/Oncology, Dana-Farber Cancer Institute, 1996-1999.
American Board of Internal Medicine (Internal Medicine), 1996.
American Board of Internal Medicine (Medical Oncology), 2000.
American Board of Internal Medicine (Medical Oncology), Recertification 2010-2020, 2010.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

Medical Oncology and Experimental Therapeutics, in particular Immunotherapy

Selected Publications

Bajor David L, Xu Xiaowei, Torigian Drew A, Mick Rosemarie, Garcia Laura R, Richman Lee P, Desmarais Cindy, Nathanson Katherine L, Schuchter Lynn M, Kalos Michael, Vonderheide Robert H: Immune Activation and a 9-Year Ongoing Complete Remission Following CD40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma. Cancer immunology research 2(11): 1051-8, Nov 2014.

Condamine Thomas, Kumar Vinit, Ramachandran Indu R, Youn Je-In, Celis Esteban, Finnberg Niklas, El-Deiry Wafik S, Winograd Rafael, Vonderheide Robert H, English Nickolas R, Knight Stella C, Yagita Hideo, McCaffrey Judith C, Antonia Scott, Hockstein Neil, Witt Robert, Masters Gregory, Bauer Thomas, Gabrilovich Dmitry I: ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. The Journal of clinical investigation 124(6): 2626-39, Jun 2014.

Zhang Yaqing, Yan Wei, Mathew Esha, Bednar Filip, Wan Shanshan, Collins Meredith A, Evans Rebecca A, Welling Theodore H, Vonderheide Robert H, di Magliano Marina Pasca: CD4+ T lymphocyte ablation prevents pancreatic carcinogenesis in mice. Cancer immunology research 2(5): 423-35, May 2014.

Richman Lee P, Vonderheide Robert H: Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer. Cancer immunology research 2(1): 19-26, Jan 2014.

Mueller Christian, Chulay Jeffrey D, Trapnell Bruce C, Humphries Margaret, Carey Brenna, Sandhaus Robert A, McElvaney Noel G, Messina Louis, Tang Qiushi, Rouhani Farshid N, Campbell-Thompson Martha, Fu Ann Dongtao, Yachnis Anthony, Knop David R, Ye Guo-Jie, Brantly Mark, Calcedo Roberto, Somanathan Suryanarayan, Richman Lee P, Vonderheide Robert H, Hulme Maigan A, Brusko Todd M, Wilson James M, Flotte Terence R: Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. The Journal of clinical investigation 123(12): 5310-8, Dec 2013.

Markosyan N, Chen EP, Evans RA, Ndong V, Vonderheide RH, Smyth EM: Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity. Breast Cancer Research 15(5): R75 [Epub ahead of print] Sep 3 2013.

Beatty GL, Torigian DA, Chiorean EG, Saboury B, Brothers A, Alavi A, Troxel AB, Sun W, Teitelbaum UR, Vonderheide RH, O'Dwyer P: A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clinical Cancer Research Page: [Epub ahead of print] Sep 4 2013.

Bayne LJ, Vonderheide RH: A myeloid-derived suppressor cell-mediated T-cell suppression assay for functional evaluation of immune cells in tumor-bearing mice. Cold Spring Harb Protoc. 2013(9), Sep 1 2013.

Vonderheide RH,Burg JM, Mick R, Trosko JA, Li D, Shaik MN, Tolcher AW, Hamid O : Phase I study of CD40 antibody CP-870,893 in combination with carboplatin and paclitaxel in patients with advanced solid tumors OncoImmunology 2: e23033, 2013.

Tchou J, Wang LC, Selven B, Zhang H, Conejo-Garcia J, Borghaei H, Kalos M, Vonderheide RH, Albelda SM, June CH, Zhang PJ. : Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Can Res Treat 133: 799-804, 2012.

back to top
Last updated: 10/05/2017
The Trustees of the University of Pennsylvania